InspireMD Ltd.

168 articles with InspireMD Ltd.

• InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020

  8/25/2020

  InspireMD, Inc. announced that Marvin Slosman, President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500 taking place online on Thursday, September 3, 2020 at 4:20 PM EST followed by a live Q&A session with registered investors and other conference attendees.

• InspireMD Regains Compliance with NYSE AMERICAN Listing Standards

  8/10/2020

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by the treatment of carotid artery disease, announced that as of August 7, 2020, the Company has regained compliance with the NYSE American’s continued listing standards.

• InspireMD Announces Second Quarter 2020 Financial Results

  8/5/2020

  In the second quarter the Company was granted approval to market itsCGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard™ MicroNET stent

• UPDATE: InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate UpdateConference Call to be held Wednesday, August 5, 2020 at 8:30am ET

  7/29/2020

  InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET.  Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments.  Following management’s fo

• InspireMD to Report Second Quarter 2020 Financial Results on Wednesday, August 5, 2020 and Provide Corporate UpdateConference Call to be held Thursday, August 5, 2020 at 8:30am ET

  7/28/2020

  InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces it will report fiscal second quarter 2020 financial results on Wednesday, August 5, 2020 at 8:00 AM ET.  Management will host a conference call at 8:30AM ET, to review financial results and provide an update on corporate developments.  Following management’s fo

• InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil

  7/23/2020

  InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced it has obtained registration from the Brazilian registration authority, Agéncia Nacional de Vigiláncia Sanitária (ANVISA), for its CGuard™ MicroNet ® - covered stent, clearing it for sale and distribution in Brazil. “As the largest market for medical devices i

• 

  Clinical Catch-Up: June 22-26

  6/29/2020

  It was a busy week for clinical trial updates. Here’s a look.

• InspireMD Announces Late-Breaking Presentation of Early SIBERIA Clinical Trial Results to be Featured in an e-Course at EuroPCR

  6/25/2020

  In a head-to-head evaluation, significantly fewer silent brain infarcts were associated with CGuard™ EPS versus Acculink™ at 30 days post-procedure

• 

  Clinical Catch-Up: June 8-12

  6/15/2020

  It was a fairly busy week with clinical trial updates and announcements. Here’s a look.

• InspireMD Announces Publication of 12-Month Results of CGuard™ EPS PARADIGM Trial in EuroIntervention

  6/10/2020

  Results indicate that 12 months after carotid intervention the CGuard EPS MicroNET-covered stent delivers sustained protection against postprocedural neurologic events TEL AVIV, Israel, June 10, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease treatment, announced today that 12-month PARADIGM trial results have been published in the EuroIntervention journal

• InspireMD, Inc. Announces Underwriter Exercise of Over-Allotment Option in Full and Closing of $11.5 Million Follow-On Underwritten Public Offering

  6/8/2020

  InspireMD, Inc. announced the closing, on June 5, 2020, of its $11.5 million follow-on underwritten public offering, which included $1.5 million from the exercise, in full, by the underwriter of its over-allotment option for the offering.

• InspireMD, Inc. Announces Pricing of $10 Million Underwritten Public Offering

  6/3/2020

  InspireMD, Inc., the developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced the pricing of an underwritten public offering of 22,222,200 units at a price to the public of $0.45 per unit.

• InspireMD Announces First Quarter 2020 Financial Results

  5/12/2020

  First quarter revenue growth driven by continued strong uptake of the CGuard™ Embolic Prevention System (EPS) in the company’s major markets

• InspireMD to Report First Quarter 2020 Financial Results and Provide Business Update on Tuesday, May 12

  5/5/2020

  InspireMD, Inc., developer of the CGuard™ Embolic Prevention System for the prevention of stroke caused by carotid artery disease, announced that management will host a conference call and webcast on Tuesday, May 12, 2020, to discuss financial results for the first quarter ended March 31, 2020, and provide a corporate update.

• InspireMD to Report Fourth Quarter 2019 Financial Results and Provide Business Update on Tuesday, March 10Management to host conference call and webcast at 8:30am ET

  3/3/2020

  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it will host a conference call and webcast on Tuesday, March 10, 2020, to discuss financial results for the fourth quarter and year ended December 31, 2019, and provide a corporate update.

• InspireMD Announces Successful Live Clinical Case Transmissions Featuring CGuard™ EPS at the Leipzig Interventional Course (LINC) 2020Case demonstrates ease-of-use and exceptional patient safety features of CGuard™ EPS

  1/29/2020

  InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, today announced that a successful live case featuring CGuard™ EPS was presented at the international LINC conference 2020, which is being held January 28 – 31 in Leipzig, Germany.

• InspireMD’s CGuard™ Embolic Prevention System to be Prominently Featured in Live Case Transmission at LINC, 28th to the 31st January 2020, in Leipzig, Germany

  1/27/2020

  Several Clinical Presentations, Updates, and Panel Discussions on CGuard EPS to also be presented

• InspireMD Announces Strong Preliminary Fourth Quarter 2019 Revenue and Reports Inducement Award Under NYSE American Company Guide §711(a)

  1/6/2020

  InspireMD, Inc. announced strong preliminary unaudited revenue for the fourth quarter and reported an inducement grant to the company’s new Chief Executive Officer, Marvin Slosman, who assumed the role effective January 1, 2020.

• InspireMD Announces Planned Leadership Transition

  12/10/2019

  Life sciences industry veteran Marvin Slosman appointed Chief Executive Officer

• 

  Clinical Catch-Up: November 25-29

  12/2/2019

  Even with a shortened week due to the U.S. Thanksgiving holiday, there was plenty of clinical trial news and updates. Here’s a look.